[1]
|
Leggio, L., Vivarelli, S., L’Episcopo, F., et al. (2017) microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. International Journal of Molecular Sciences, 18, pii: E2698.
https://doi.org/10.3390/ijms18122698
|
[2]
|
Gui, Y.X., Liu, H., Zhang, L.S., et al. (2015) Altered microRNA Pro-files in Cerebrospinal Fluid Exosome in Parkinson Disease and Alzheimer Disease. Oncotarget, 6, 37043-37053. https://doi.org/10.18632/oncotarget.6158
|
[3]
|
Sarko, D.K. and Mckinney, C.E. (2017) Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease. Frontiers in Neuroscience, 11, 82. https://doi.org/10.3389/fnins.2017.00082
|
[4]
|
Kelly, P.S., Breen, L., Gallagher, C., et al. (2015) Re-Programming CHO Cell Metabolism Using miR-23 Tips the Balance towards a Highly Productive Phenotype. Biotechnology Journal, 10, 1029-1040.
https://doi.org/10.1002/biot.201500101
|
[5]
|
Qiu, L., Zhang, W., Tan, E.K., et al. (2014) Deciphering the Function and Regulation of microRNAs in Alzheimer’s Disease and Parkinson’s Disease. ACS Chemical Neuroscience, 5, 884. https://doi.org/10.1021/cn500149w
|
[6]
|
De, T.J., Herschlik, L., Waldner, C., et al. (2015) Emerging Roles of Exosomes in Normal and Pathological Conditions: New Insights for Diagnosis and Therapeutic Applications. Frontiers in Immunology, 6, 203.
https://doi.org/10.3389/fimmu.2015.00203
|
[7]
|
Stuendl, A., Kunadt, M., Kruse, N., et al. (2016) Induction of α-Synuclein Aggregate Formation by CSF Exosomes from Patients with Parkinson’s Disease and Dementia with Lewy Bodies. Brain, 139, 481-494.
https://doi.org/10.1093/brain/awv346
|
[8]
|
Danzer, K.M., Kranich, L.R., Ruf, W.P., et al. (2012) Exosomal Cell-to-Cell Transmission of Alpha Synuclein Oligomers. Molecular Neurodegeneration, 7, 42. https://doi.org/10.1186/1750-1326-7-42
|
[9]
|
Gaspar, R., Meisl, G., Buell, A.K., et al. (2017) Acceleration of α-Synuclein Aggregation. Amyloid, 24, 20-21.
https://doi.org/10.1080/13506129.2017.1292904
|
[10]
|
Henning, U., Cristina, I., et al. (2015) Immunomodulation in Stem Cell Differentiation into Neurons and Brain Repair. Stem Cell Reviews and Reports, 11, 474-486. https://doi.org/10.1007/s12015-014-9556-6
|
[11]
|
Hu, R., Kagele, D.A., Huffaker, T.B., et al. (2014) MiR-155 Promotes T Follicular Helper Cell Accumulation during Chronic, Low-Grade Inflammation. Immunity, 41, 605-619. https://doi.org/10.1016/j.immuni.2014.09.015
|
[12]
|
Doxakis, E. (2010) Post-Transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153. Journal of Biological Chemistry, 285, 12726-12734. https://doi.org/10.1074/jbc.M109.086827
|
[13]
|
Guo, J.F., Zhang, L. and Li, K. (2018) Coding Mutations in NUS1 Contribute to Parkinson’s Disease. Proceedings of the National Academy of Sciences, 115, 11567-11572.
|
[14]
|
Chang, D., Nalls, M.A., Hunkapiller, J., et al. (2017) A Meta-Analysis of Genome-Wide Association Studies Identifies 17 New Parkinson’s Disease Risk Loci. Nature Genetics, 49, 1511. https://doi.org/10.1038/ng.3955
|
[15]
|
Chen, Q., Huang, X. and Li, R. (2018) lncRNA MALAT1/miR-205-5p Axis Regulates MPP+-Induced Cell Apoptosis in MN9D Cells by Directly Targeting LRRK2. American Journal of Translational Research, 10, 563.
|
[16]
|
Zhang, Z. and Cheng, Y. (2014) miR-16-1 Promotes the Aberrant\r, α\r, -Synuclein Accumulation in Parkinson Disease via Targeting Heat Shock Protein 70. The Scientific World Journal, 2014, Article ID: 938348.
https://doi.org/10.1155/2014/938348
|
[17]
|
Moyano, E.M., Porta, S., Escaramís, G., et al. (2011) MicroRNA Pro-filing of Parkinson’s Disease Brains Identifies Early Downregulation of miR-34b/c Which Modulate Mitochondrial Function. Human Molecular Genetics, 20, 3067-3078. https://doi.org/10.1093/hmg/ddr210
|
[18]
|
Kumar, S., Vi-jayan, M., Bhatti, J.S., et al. (2017) Chapter Three—MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. Progress in Molecular Biology and Translational Science, 146, 47-94.
https://doi.org/10.1016/bs.pmbts.2016.12.013
|
[19]
|
West, A.B., Cowell, R.M., Daher, J.P.L., et al. (2014) Differ-ential LRRK2 Expression in the Cortex, Striatum, and Substantia Nigra in Transgenic and Nontransgenic Rodents. Journal of Comparative Neurology, 522, 2465-2480.
https://doi.org/10.1002/cne.23583
|
[20]
|
Wang, S., Liu, Z., Ye, T., et al. (2017) Elevated LRRK2 Autophosphory-lation in Brain-Derived and Peripheral Exosomes in LRRK2 Mutation Carriers. Acta Neuropathologica Communications, 5, 86.
https://doi.org/10.1186/s40478-017-0492-y
|
[21]
|
Riley, B.E., Gardai, S.J., Emig-Agius, D., et al. (2014) Sys-tems-Based Analyses of Brain Regions Functionally Impacted in Parkinson’s Disease Reveals Underlying Causal Mechanisms. PLoS ONE, 9, e102909.
https://doi.org/10.1371/journal.pone.0102909
|
[22]
|
Fraser, K.B., Moehle, M.S., Daher, J.P., et al. (2013) LRRK2 Secretion in Exosomes Is Regulated by 14-3-3. Human Molecular Genetics, 22, 4988-5000. https://doi.org/10.1093/hmg/ddt346
|
[23]
|
Ho, D.H., Yi, S., Seo, H., et al. (2014) Increased DJ-1 in Urine Exosome of Korean Males with Parkinson’s Disease. Biomed Research International, 2014, Article ID: 704678. https://doi.org/10.1155/2014/704678
|
[24]
|
Fraser, K.B., Moehle, M.S., Alcalay, R.N., et al. (2016) Urinary LRRK2 Phosphorylation Predicts Parkinsonian Phenotypes in G2019S LRRK2 Carriers. Neurology, 86, 994-999. https://doi.org/10.1212/WNL.0000000000002436
|
[25]
|
Fraser, K.B., Rawlins, A.B., Clark, R.G., et al. (2016) Ser(P)-1292 LRRK2 in Urinary Exosomes Is Elevated in Idiopathic Parkinson’s Disease. Movement Disorders Official Journal of the Movement Disorder Society, 31, 1543-1550.
https://doi.org/10.1002/mds.26686
|
[26]
|
Aitken, J., Lay, P., Park, J.S., et al. (2014) Parkinson’s Disease-Linked Human PARK9/ATP13A2 Maintains Zinc Homeostasis and Promotes Alpha-Synuclein Externalization via Exosomes. Human Molecular Genetics, 23, 2816.
https://doi.org/10.1093/hmg/ddu099
|
[27]
|
Alvarez-Erviti, L., Seow, Y., Schapira, A.H., et al. (2011) Lysosomal Dysfunction Increases Exosome-Mediated Alpha-Synuclein Release and Transmission. Neurobiology of Disease, 42, 360-367.
https://doi.org/10.1016/j.nbd.2011.01.029
|
[28]
|
Chang, C., Lang, H., Geng, N., et al. (2013) Exosomes of BV-2 Cells Induced by Alpha-Synuclein: Important Mediator of Neurodegeneration in PD. Neuroscience Letters, 548, 190-195. https://doi.org/10.1016/j.neulet.2013.06.009
|
[29]
|
Isra, Z., Anas, N. and Rafik, K. (2018) Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review. Molecules, 23, pii: E1289. https://doi.org/10.3390/molecules23061289
|
[30]
|
Lai, R.C., Yeo, R.W.Y., Tan, K.H., et al. (2013) Exosomes for Drug Delivery—A Novel Application for the Mesenchymal Stem Cell. Biotechnology Advances, 31, 543-551. https://doi.org/10.1016/j.biotechadv.2012.08.008
|
[31]
|
Tetsuhiro, K., Asuka, M., Daisuke, D., et al. (2017) Human iPS Cell-Derived Dopaminergic Neurons Function in a Primate Parkinson’s Disease Model. Nature, 548, 592-596. https://doi.org/10.1038/nature23664
|
[32]
|
Alejandro, L., Federico, B.L., Ursula, W., et al. (2016) Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche. Stem Cells International, 2016, Article ID: 5736059.
https://doi.org/10.1155/2016/5736059
|
[33]
|
Chang, Y.H., Wu, K.C., Harn, H.J., et al. (2018) Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy. Cell Transplantation, 27, 349-363.
|
[34]
|
Jarmalavičiūtė, A., Tunaitis, V., Pivoraitė, U., et al. (2015) Exosomes from Dental Pulp Stem Cells Rescue Human Dopaminergic Neurons from 6-Hydroxy-Dopamine-Induced Apoptosis. Cytotherapy, 17, 932-939.
https://doi.org/10.1016/j.jcyt.2014.07.013
|
[35]
|
Qu, M., et al. (2018) Dopamine-Loaded Blood Exosomes Targeted to Brain for Better Treatment of Parkinson’s Disease. Journal of Controlled Release, 287, 156-166.
|
[36]
|
Cooper, J.M., Wiklander, P.B.O., Nordin, J.Z., et al. (2015) Systemic Exosomal siRNA Delivery Reduced Alpha-Synuclein Aggregates in Brains of Transgenic Mice. Movement Disorders Official Journal of the Movement Disorder Society, 29, 1476-1485. https://doi.org/10.1002/mds.25978
|
[37]
|
González-Polo, R.A., Soler, G., Morán, J.M., et al. (2013) Protection against MPP+ Neurotoxicity in Cerebellar Granule Cells by Antioxidants. Cell Biology International, 28, 373-380. https://doi.org/10.1016/j.cellbi.2004.03.005
|
[38]
|
Haney, M.J., Klyachko, N.L., Zhao, Y., et al. (2015) Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy. Journal of Controlled Release Official Journal of the Controlled Release Society, 207, 18-30.
https://doi.org/10.1016/j.jconrel.2015.03.033
|
[39]
|
Silva, A.K.A., Luciani, N., Gazeau, F., et al. (2015) Combining Magnetic Nanoparticles with Cell Derived Microvesicles for Drug Loading and Targeting. Nanomedicine Nano-technology Biology & Medicine, 11, 645-655.
https://doi.org/10.1016/j.nano.2014.11.009
|
[40]
|
Liu, C., Feng, Q. and Sun, J. (2018) Lipid Nanovesicles by Mi-crofluidics: Manipulation, Synthesis, and Drug Delivery. Advanced Materials. https://doi.org/10.1002/adma.201804788
|